Half-year liquidity contract statement for LYSOGENE

Half-year liquidity contract statement for LYSOGENE 150 150 Lysogene

Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.

Under the liquidity contract entered into between LYSOGENE and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:

–   43,579 shares

–   € 132,063.33

–   Number of executions on buy side on semester: 369

–   Number of executions on sell side on semester: 399

–   Traded volume on buy side on semester: 125,130 shares for € 358,888.31

–   Traded volume on sell side on semester: 131,937 shares for € 400,135.60

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account:

–   50,386 shares

–   € 91,098.95

–   Number of executions on buy side on semester: 303

–   Number of executions on sell side on semester: 278

–   Traded volume on buy side on semester: 96,720 shares for € 217,955.50

–   Traded volume on sell side on semester: 90,522 shares for € 215,280.25

  • the following resources appeared on the liquidity account when the activity started:

–   34,030 shares

–   € 78,185.94

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

Buy SideSell Side 
Number of executionsNumber of sharesTraded volume (€)Number of executionsNumber of sharesTraded volume (€) 
Total369125,130358,888.31399131,937400,135.60 
04/01/20211525007 025.00 
05/01/202173 3999 143.3115001 425.00 
06/01/202115001 325.0025001 370.00 
07/01/202115001 370.00 
08/01/202161 5003 900.0035001 350.00 
11/01/202115950029 450.00 
12/01/202164 50012 420.00 
13/01/202174 00010 640.00 
14/01/202115001 325.00 
15/01/202121 0002 580.00 
18/01/202161 5003 750.0015001 300.00 
19/01/202115001 250.0015001 275.00 
20/01/202141 0002 480.00 
21/01/2021615003 825.00 
22/01/202161 5003 750.00 
25/01/2021165 00011 700.001150375.00 
26/01/202125001 150.0015001 175.00 
27/01/2021420004 980.00 
28/01/202142 0004 620.00 
29/01/202135001 150.00 
01/02/202115700017 500.00 
02/02/202115001 250.0015001 300.00 
03/02/202116500013 400.00 
04/02/202114500014 550.00 
05/02/202141 5004 200.00615004 425.00 
08/02/202114500015 400.00 
09/02/202192 7008 343.00 
10/02/202172 0005 960.00210003 140.00 
11/02/202131 0002 900.0018906929 111.49 
12/02/202121 0003 680.0033750027 900.00 
15/02/202125001 925.0020700029 540.00 
16/02/2021216 53624 117.84 
17/02/2021146 22121 586.8715001 850.00 
18/02/2021166 80421 772.80 
19/02/202131 5004 635.00930009 840.00 
22/02/202121 0003 230.00820006 760.00 
Buy SideSell Side
Number of executionsNumber of sharesTraded volume (€)Number of executionsNumber of sharesTraded volume (€)
23/02/2021234 50014 985.00420007 160.00
24/02/202115001 625.00310003 280.00
25/02/202112400013 640.00
26/02/202193 50011 410.00710003 380.00
01/03/2021611573 899.09
02/03/202125001 645.00
03/03/202162 0006 380.00
04/03/2021113 50010 815.00
05/03/202151 5004 500.00
08/03/202125001 475.0025001 510.00
09/03/202115001 475.00820066 278.78
10/03/202115001 550.0034941 556.10
11/03/202115001 575.00
12/03/202135001 575.00
15/03/202121 0003 060.00
16/03/202115001 500.00
17/03/2021310003 030.00
18/03/202135001 495.00
19/03/2021102 0005 760.00
22/03/202131 0002 880.00310002 930.00
23/03/202115001 425.00
24/03/202121 0002 780.00
25/03/202141 0002 730.0015001 420.00
26/03/202125001 375.00
29/03/2021410002 830.00
30/03/202115001 400.0045001 450.00
31/03/2021310002 880.00
01/04/202115001 395.0015001 425.00
06/04/202125001 400.00
08/04/2021112.7925011 402.80
09/04/202125001 400.0015001 425.00
12/04/202115001 400.00
13/04/2021315004 350.00
14/04/202121 0002 880.00
15/04/20212201570.84
Buy SideSell Side
Number of executionsNumber of sharesTraded volume (€)Number of executionsNumber of sharesTraded volume (€)
16/04/20211720.30
19/04/202114931 429.70
20/04/202135001 400.00
21/04/202115001 375.00
22/04/202131 0002 930.00930008 940.00
23/04/202141 5004 260.00
26/04/202115001 400.00
27/04/202125001 400.0035001 425.00
28/04/2021410002 830.00
29/04/202135001 400.00
30/04/202145001 375.00
03/05/202125001 400.00
06/05/202115001 375.00
07/05/202125001 375.00
11/05/202192 0005 260.0015001 325.00
12/05/202141 5003 825.00
13/05/202162 0004 960.00
14/05/202114400010 760.00
17/05/202125001 300.0015001 350.00
18/05/2021112.633226598.90
19/05/2021112.63112.63
20/05/202145001 275.00
24/05/202141 0002 580.0037752 030.50
25/05/202172 0004 960.0015001 300.00
26/05/202171 5003 630.002272680.00
27/05/202131 5003 525.00
02/06/202115001 175.00
03/06/2021210002 430.00
04/06/202145001 200.00
07/06/202157281 798.16
08/06/2021725006 575.00
09/06/202183 8699 788.57
10/06/202113500013 300.00
11/06/202121900027 000.00
14/06/202131 5004 275.00
15/06/202132 0005 520.00410002 930.00
16/06/2021104 89612 729.6015001 400.00
Buy SideSell Side
Number of executionsNumber of sharesTraded volume (€)Number of executionsNumber of sharesTraded volume (€)
17/06/202152 0004 980.00
18/06/202121 0002 430.0025001 250.00
21/06/202115001 175.00
22/06/2021410002 430.00
23/06/2021112.43415013 752.50
24/06/2021210002 480.00
25/06/202125001 200.00
28/06/202125001 175.00157139.65
30/06/202121 0002 280.0015001 175.00

About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive clinical trial in GM1 gangliosidosis is ongoing. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Forward Looking Statement    

This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Contacts
Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.